SUPPLEMENTARY MATERIALS. Appendix 1. Definition of Suicidal Behavior Using ICD-9 Diagnostic Codes.
|
|
- Lizbeth Caldwell
- 5 years ago
- Views:
Transcription
1 SUPPLEMENTARY MATERIALS Appendix 1. Definition of Suicidal Behavior Using ICD-9 Diagnostic Codes. For this study, suicidal behavior was defined using ICD-9 diagnostic codes and death certificates from the Commonwealth of Massachusetts. ICD-9 codes of E95* (injuries of intentional intent) are the most explicit diagnostic code for suicide attempts. In order to validate our case definition, we randomly selected 100 patients with an E95* code and reviewed all clinical notes within one week of the ICD-9 diagnosis. Three senior clinicians with expertise in the epidemiology and treatment of suicidal behavior (JWS, RHP, MKN) manually reviewed narrative notes. Each note was designated as one of six categories using consensus agreement by all three clinicians: (1) Self-harm, suicidal, (2) Self-harm, intentional, non-suicidal, (3) Self-harm, accidental, (4) Self-harm, not enough intent information, (5) Self-harm, contradictory intent information and (6) No evidence of selfharm. The positive predictive value (PPV) of each code was calculated as the proportion of notes classified in categories 1 or 2. To maximize sensitivity of the case definition we identified an additional set of 15 ICD-9 injury code categories as well as E98* (injury of questionable intent) as potential indicators of suicide attempts in the EHR (Table S-1). For each ICD-9 category, the clinicians reviewed a small sample of patients using the chart review method above. If the prevalence of true cases was > 20%, a larger sample of 50 randomly selected patients were subsequently reviewed. Code categories with a PPV > 0.70 were selected for our final case definition. These included E95* (PPV: 0.82), 965.* (Poisoning by analgesics, antipyretics, and anti-rheumatics, PPV: 0.80), 967.* (Poisoning by sedatives and hypnotics, PPV: 0.84), 969.* (Poisoning by psychotropic agents, PPV: 0.80) and 881.* (Open wound of elbow
2 forearm and wrist, PPV: 0.70). Detailed chart review results, including codes not included in the definition are available in Supplementary Table S-1. We searched death certificates for a primary or underlying cause of death of suicide as defined by the state (ie ICD-10 X60-X84, Y87.0, ICD-9 E950-E959). In Massachusetts, all deaths by suicide, homicide, deaths under suspicious or unusual circumstances and deaths due to poison or acute or chronic use of drugs or alcohol are referred to the medical examiner to establish the cause of death (MGL Ch. 38, Section 3) and 99.6% were reviewed by the medical examiner. While this may have resulted in our missing true cases, the effect would be expected to reduce the accuracy of our model (as these cases would have been included among controls). Thus our model accuracy metrics may be conservative and we now note this as a limitation of the study. Also, as noted in the main text, of the 852 death certificates with suicide as a cause of death, only 49 didn t have one of the ICD9 codes that comprise the case definition, supporting the assumption that our case definition of suicide attempt captures most individuals who completed suicide.
3 Appendix 2. Development of the Naïve Bayes Classifier Model To build the Naïve Bayes classifier we calculated the odds-ratio associated with each feature used in the model. We then calculated the log of the odds-ratio, converting ratios that are larger than one (more common among cases) into positive scores and ratios that are between zero and one (more common among controls) into negative scores. For example, Opioid abuse, unspecified use was recorded for 366 cases (out of a total of 627,121different ICD-9 codes recorded for the cases) and for 2,073 controls (out of a total of 53,596,375 ICD-9 codes recorded for the controls). Thus, the odds-ratio was: (366/627,121) / (2,073/53,596,375) = To calculate the Naïve Bayes score we took the natural log of the odds-ratio to get a score of: ln(15.09) = 2.71 The same process was repeated for all different variables. Once we had a Naïve Bayes score for each individual variable, we applied these scores for each subject over time and calculated the total cumulative score. Thus, if a subject X had a documentation of Opioid abuse, unspecified use at a specific time T, then their score from time T-1 will increase by 2.71 points.
4 Table S-1 Sample sets and PPV by diagnostic codes reviewed for inclusion in the case definition. This table shows the number of patients in the Partners Electronic Medical Records who were assigned each code. A. ICD-9 Codes selected for inclusion in the case definition, based on clinician chart review that showed a PPV > 0.70 for suicide attempts and death by suicide. ICD-9 codes: E95* 965.* 967.* 969.* 881.* Case definition N in Partners EMR 6,364 3, ,906 9,517 20,246 (1) Self harm suicidal (2) Self harm - intentional, nonsuicidal (3) Self harm - accidental (4) Self harm - not enough intent information (5) Self harm - contradictory intent information (6) No evidence of self-harm Total PPV (Self harm (1) only) PPV (including (1) and (2)) B. ICD-9 Codes with suicide attempt PPV < 0.70 not included in the case definition ICD-9 codes: E98* E * 966.* 986.* 970.* E868.* 968. * N in Partners EMR 3, ,737 1, (1) Self harm - suicidal (2) Self harm - intentional, nonsuicidal (3) Self harm - accidental (4) Self harm - not enough intent information (5) Self harm - contradictory intent information (6) No evidence of self-harm Total PPV (Self harm (1) only) PPV (including (1) and (2))
5 Table S-2 - List of top 100 diagnoses, medications, and lab results associated with suicidal behavior, along with their incidence and associated risk-score. The incidence of each code and shown on a 1:100,000 codes ratio. The risk score for each code is calculated as the relative prevalence of the code among cases divided by the relative prevalence among controls. 95% Confidence Intervals (CI) are shown in brackets. A. Top 100 diagnostic and procedure codes associated with suicidal behavior. Diagnoses and Procedures Cases (1:100k) Controls (1:100k) TOTAL Women Men Risk Score [95% CI] Risk Score [95% CI] Risk Score [95% CI] Opioid abuse, continuous use [ ] [ ] 15.8 [ ] Other, mixed, or unspecified drug abuse, continuous use [ ] 17.9 [ ] 16.8 [ ] Combinations of opioid type drug with any other drug dependence, continuous use [ ] 16.7 [ ] [ ] Combinations of opioid type drug with any other drug dependence, unspecified use [ ] [ ] [ ] Poisoning by unspecified drug or medicinal substance [ ] [ ] [ ] Cocaine dependence, continuous use [ ] [ ] 14.5 [ ] Opioid abuse, unspecified use [ ] [ ] [ ] Barbiturate and similarly acting sedative or hypnotic abuse, unspecified use [ ] [ ] [ ] Cocaine abuse, continuous use [ ] 9.51 [ ] [9.2-15] Opioid type dependence, continuous use [ ] [8.1-13] [9.7-14] Drug withdrawal syndrome [ ] 10.7 [ ] 10.2 [ ] Other, mixed, or unspecified drug abuse, unspecified use [ ] [ ] 9.3 [ ] Combinations of drug dependence excluding opioid type drug, unspecified use [ ] [ ] 8.89 [ ] Acute alcoholic intoxication in alcoholism, unspecified drinking behavior [ ] [ ] 8.45 [7.1-10] Borderline personality [ ] [ ] 8.88 [ ] Unspecified neurotic disorder [8.9-11] [ ] 8.95 [ ] Acute alcoholic intoxication in alcoholism, continuous drinking behavior [ ] [ ] 7.47 [ ] Cocaine abuse, unspecified use [ ] [ ] 8 [7-9.2] Barbiturate and similarly acting sedative or hypnotic dependence, unspecified use [ ] 9.83 [7-13.8] 9.08 [ ] Cocaine dependence, unspecified use [ ] [ ] 8.45 [ ] Drug-induced organic affective [ ] 9.55 [ ] 8.78 [ ]
6 syndrome Opioid type dependence, unspecified use [8.2-10] 9.18 [ ] 8.33 [ ] Opioid abuse, in remission [ ] 8.46 [5-14.4] 8.55 [6-12.3] Lack of housing [ ] 8.23 [ ] 8.11 [ ] Depressive neuroses [ ] 8.26 [ ] 8.31 [ ] Alcohol/drug abuse or dependence w cc [ ] 9.76 [ ] 6.79 [5.1-9] Bipolar affective disorder, depressed, severe degree, specified as with psychotic behavior [ ] 6.68 [ ] 9.29 [ ] Unspecified drug dependence, unspecified use [ ] 7.86 [ ] 6.99 [6-8.1] Closed fracture of rib(s) [ ] 8.46 [ ] 6.08 [ ] Opioid type dependence, in remission [ ] 7.81 [ ] 6.35 [ ] Psychoses [ ] 7.1 [ ] 6.85 [ ] Open wound of hand except fingers alone, with tendon involvement [ ] [ ] 5.12 [ ] Cocaine abuse, episodic use [ ] [5.4-20] 5.01 [ ] Other, mixed, or unspecified drug abuse, in remission [ ] 7.32 [ ] 6.15 [ ] Other and unspecified alcohol dependence [ ] 7.83 [ ] 5.88 [ ] Unspecified personality disorder [ ] 8.28 [ ] 5.12 [ ] Assault by cutting and piercing instrument [ ] 5.12 [ ] 6.07 [ ] Bipolar affective disorder, mixed [ ] 7.34 [ ] 5.79 [3-11] Nontraumatic rupture of extensor tendons of hand and wrist [ ] [ ] 3.5 [ ] Unspecified schizophrenia, chronic state [ ] 8.24 [ ] 5.01 [ ] Schizo-affective type schizophrenia, chronic state with acute exacerbation [ ] 5.28 [2.3-12] 6.75 [ ] Observation following other inflicted injury [ ] 8.02 [ ] 4.72 [ ] Other and unspecified alcohol dependence, continuous drinking behavior [ ] 7.51 [ ] 5.22 [ ] Hepatitis C carrier [ ] 6.49 [ ] 5.39 [ ] Major depressive disorder, single episode, severe degree, specified as with psychotic behavior [ ] 5.95 [3.9-9] 6.13 [4-9.4] Unspecified drug-induced mental disorder [4-9.2] 6.48 [ ] 5.39 [ ]
7 Schizo-affective type schizophrenia, chronic state [3.6-10] 5.79 [ ] 6.02 [ ] Alcohol/drug abuse or depend w/o rehabilitation therapy w/o cc [ ] 5.95 [ ] 5.43 [ ] Bipolar affective disorder, depressed, moderate degree [ ] 7.45 [ ] 4.09 [2.1-8] Bipolar affective disorder, depressed, unspecified degree [ ] 6.26 [ ] 5.51 [ ] Other electroshock therapy [ ] 6.1 [4-9.4] 5.68 [ ] Alcohol withdrawal [ ] 8.15 [ ] 4.74 [ ] Alveolitis of jaw [ ] 4.91 [ ] 7.36 [ ] Bipolar affective disorder, unspecified [ ] 6.47 [ ] 4.87 [ ] Bipolar affective disorder, mixed, severe degree, without mention of psychotic behavior [ ] 7.64 [ ] 2.72 [1-7.4] Debridement of open fracture of radius and ulna [ ] 4.32 [ ] 6.34 [ ] Issue of repeat prescriptions [ ] 4.55 [ ] 6.01 [ ] Bipolar affective disorder, mixed, severe degree, specified as with psychotic behavior [ ] 4.94 [ ] 6.64 [3.7-12] Paranoid type schizophrenia, chronic state [ ] 6.05 [2.8-13] 4.73 [ ] Alcoholic gastritis, without mention of hemorrhage [ ] 6.43 [ ] 4.47 [ ] Acute adjustment reaction and psychosocial dysfunction [ ] 5.08 [3.2-8] 5.57 [ ] Major depressive disorder, recurrent episode [ ] 6.79 [ ] 2.54 [ ] Manic disorder, single episode, unspecified degree [ ] 5.96 [4.4-8] 4.44 [3-6.5] Other and unspecified alcohol dependence, unspecified drinking behavior [ ] 5.7 [ ] 4.56 [4.1-5] Bipolar affective disorder, mixed, unspecified degree [ ] 5.97 [ ] 4.37 [ ] Cannabis dependence, unspecified use [4-6.7] 4.69 [ ] 4.88 [ ] Bipolar affective disorder, depressed, severe degree, without mention of psychotic behavior [4-6.7] 5.83 [4.2-8] 4.44 [ ] Other and unspecified reactive psychosis [ ] 7.97 [ ] 2.85 [1.6-5] Alcohol abuse, unspecified drinking behavior [ ] 6.14 [ ] 4.2 [ ]
8 Multiple and unspecified open wound of upper limb, without mention of complication [4-6.4] 5.08 [ ] 4.67 [ ] Late effect of tendon injury [ ] 5.05 [ ] 4.65 [ ] Cannabis abuse, unspecified use [4.2-6] 6.76 [ ] 3.9 [ ] Counseling on substance use and abuse [ ] 4.86 [ ] 4.95 [ ] Poisoning and toxic effects of drugs age >17 w cc [ ] 3.44 [ ] 5.84 [3.8-9] Other and unspecified injury to head, face, and neck [ ] 5.87 [3-11.5] 4.19 [ ] Schizo-affective type schizophrenia, unspecified state [ ] 4.78 [ ] 4.96 [4-6.1] Alcohol detoxification [3.5-7] 3.31 [1.2-9] 4.7 [ ] Alcohol abuse, episodic drinking behavior [ ] 6.54 [ ] 3.91 [ ] Trauma To The Skin, Subcut Tiss and Breast Age >17 W CC [ ] 5.1 [ ] 4.49 [ ] Bipolar affective disorder, manic, unspecified degree [ ] 5.67 [ ] 4.03 [3.3-5] Osteomyelitis [2.9-8] 4.32 [ ] 4.73 [ ] Assault by other specified means [ ] 6.1 [ ] 3.63 [ ] Assault by striking by blunt or thrown object [ ] 6.25 [ ] 3.98 [3-5.3] Assault by unspecified means [4-5.8] 6.04 [ ] 3.96 [3.2-5] Unspecified affective psychosis [ ] 5.02 [ ] 4.4 [4-4.9] Residual schizophrenia, unspecified state [ ] 8.21 [ ] 2.41 [ ] Open wound of abdominal wall, lateral, without mention of complication [ ] 3.72 [ ] 4.63 [ ] Major depressive disorder, recurrent episode, severe degree, specified as with psychotic behavior [4-5.6] 5.39 [ ] 3.95 [ ] Contusion of back [ ] 5.72 [ ] 3.66 [ ] Prolonged posttraumatic stress disorder [ ] 4.96 [ ] 4.59 [ ] Alcohol abuse, continuous drinking behavior [4-5.5] 5.87 [ ] 3.9 [ ] Injury to unspecified blood vessel of head and neck [ ] 3.96 [ ] 4.73 [ ] Acute or unspecified hepatitis C without mention of hepatic coma [ ] 4.3 [ ] 4.5 [ ] Alcohol withdrawal delirium [3.6-6] 5.74 [ ] 3.89 [ ] Major depressive disorder, single episode, unspecified degree [4.3-5] 4.58 [ ] 4.82 [ ]
9 Chronic hepatitis C without mention of hepatic coma [ ] 4.72 [ ] 4.21 [ ] Cellulitis and abscess of hand, except fingers and thumb [ ] 5.42 [4.2-7] 3.76 [3-4.8] Cocaine abuse, in remission [ ] 4.34 [ ] 4.17 [ ] Other suture of other tendon of hand [ ] 4.92 [2.4-10] 3.93 [2.6-6] Other manic-depressive psychosis [ ] 5.15 [ ] 3.7 [ ] B. Top 100 medications associated with suicidal behavior. Medication Cases (1:100k) TOTAL Women Men Controls Risk Score [95% CI] Risk Score [95% CI] Risk Score [95% CI] (1:100k) Fluphenazine [ ] 5.05 [ ] 8.03 [ ] Buprenorphine- Naloxone [ ] 6.53 [ ] 5.35 [ ] Ziprasidone [ ] 5.16 [3.8-7] 7.18 [ ] Lithium [5-6.5] 6.61 [ ] 4.68 [ ] Disulfiram [ ] 3.27 [1-10.3] 5.12 [ ] Naltrexone [ ] 6.16 [ ] 3.07 [1.9-5] Chlordiazepoxide [ ] 3.88 [ ] 4.59 [ ] Methadone [4-5.1] 4.33 [ ] 4.5 [ ] Stavudine [ ] 4.87 [ ] 3.77 [ ] Nefazodone [ ] 3.79 [ ] 5.08 [ ] Benztropine [3.6-5] 4.55 [ ] 3.82 [3-4.9] Hydrocodone [ ] 6.15 [ ] 0.7 [0.1-5] Acamprosate [ ] 4.85 [ ] 3 [ ] Clonidine [ ] 3.61 [ ] 3.81 [ ] Risperidone [ ] 4.14 [ ] 3.26 [ ] Aripiprazole [ ] 4.23 [3.6-5] 3.05 [ ] Divalproex Sodium [ ] 3.81 [ ] 3.46 [3-4.1] Oxcarbazepine [ ] 3.75 [ ] 3.55 [ ] Clozapine [ ] 3.99 [ ] 3.2 [ ] Nelfinavir [2-6.3] 6.86 [3.4-14] 1.7 [ ] Mafenide Topical [ ] 5.51 [ ] 2.49 [ ] Quetiapine [ ] 3.89 [ ] 3.1 [ ] Fluvoxamine [ ] 3.91 [ ] 2.73 [ ] Clomipramine [2-5.5] 4.79 [ ] 1.94 [ ] Nicotine [ ] 3.46 [ ] 3.08 [ ] Zafirlukast [ ] 3.59 [ ] 2.84 [ ] Lamivudine [ ] 4.4 [ ] 2.54 [1.6-4] Trimethobenzami de [ ] 3.11 [ ] 3.75 [ ] Lindane Topical [ ] 0.73 [ ] 5.78 [ ]
10 Dicyclomine [ ] 2.29 [1.8-3] 4.44 [ ] Chlorpromazine [ ] 6.08 [ ] 1.94 [ ] Zidovudine [ ] 3.4 [ ] 2.58 [ ] Phenobarbital [ ] 2.92 [ ] 2.69 [ ] Olanzapine [ ] 3.12 [ ] 2.52 [ ] Paliperidone [ ] 1.96 [ ] 3.54 [ ] Bacitracin Topical [ ] 3.32 [ ] 2.35 [ ] Ribavirin [ ] 2.79 [ ] 2.6 [ ] Candida Albicans Extract [2-3.9] 3.83 [ ] 2.01 [ ] Thiamine [2.5-3] 2.62 [ ] 2.57 [ ] Mumps Skin Test Antigen [ ] 3.96 [ ] 1.78 [1-3.1] Prazosin [2-3.5] 4.13 [3-5.8] 1.47 [ ] Interferon Alfa-2a [ ] 3.13 [ ] 2.24 [ ] Efavirenz [ ] 2.67 [ ] 2.4 [1.5-4] Bupropion [ ] 2.77 [ ] 2.46 [ ] Lamotrigine [2.3-3] 3.03 [ ] 1.99 [ ] Hexachlorophene Topical [ ] 0.84 [0.1-6] 3.76 [ ] Clonazepam [ ] 2.61 [ ] 2.58 [ ] Urokinase [ ] 2.82 [ ] 2.26 [ ] Doxepin [2-3.1] 2.48 [ ] 2.64 [ ] Mirtazapine [ ] 2.42 [2-2.9] 2.56 [2.2-3] Methylnaltrexone [ ] 3.16 [ ] 1.91 [ ] Triethanolamine Polypeptide Oleate Otic [ ] 3.8 [ ] 0.82 [ ] Interferon Alfa-2a [ ] 2.61 [1-7] 2.2 [ ] Atazanavir [1.4-4] 2.6 [ ] 2.12 [1.1-4] Carisoprodol [ ] 2.55 [ ] 2.21 [ ] Iron Dextran [ ] 3.19 [ ] 1.39 [ ] Bretylium [1-5.6] 3.23 [1-10.2] 1.54 [ ] Quinine [ ] 2.61 [2-3.5] 1.92 [ ] Chlordiazepoxide- Clidinium [ ] 2.69 [ ] 1.46 [ ] Choline Salicylate- Magnesium Salicylate [ ] 2.21 [ ] 2.45 [ ] Abacavir [ ] 2.42 [ ] 1.98 [ ] Tiagabine [1-5] 1.9 [ ] 2.71 [ ] Lanolin Topical [1.2-4] 2.45 [ ] 1.95 [ ] Trazodone [ ] 2.26 [ ] 2.12 [ ] Paroxetine [2-2.4] 2.09 [ ] 2.44 [ ] Ritonavir [ ] 2.47 [ ] 1.92 [ ] Selegiline [ ] 3.3 [ ] 1.25 [ ] Ramelteon [ ] 3.21 [ ] 0.8 [ ] Desipramine [1.6-3] 2.61 [ ] 1.52 [ ]
11 Ticlopidine [ ] 1.61 [ ] 2.23 [ ] Haloperidol [2-2.4] 2.51 [ ] 1.81 [ ] Lamivudine- Zidovudine [ ] 2.82 [ ] 1.61 [ ] Al Hydroxide/Mg Hydroxide/Simethi cone [ ] 2.11 [ ] 2.11 [ ] Amphotericin B Topical [ ] 3.13 [ ] 1.42 [ ] Carbamazepine [ ] 2.35 [1.8-3] 1.85 [ ] Fluoxetine [ ] 2.13 [ ] 2.24 [2-2.6] Salsalate [ ] 2.6 [1.7-4] 1.38 [ ] Theophylline [ ] 2.54 [ ] 1.59 [1-2.6] Perphenazine [ ] 2.71 [ ] 1.34 [0.9-2] Venlafaxine [ ] 2.12 [ ] 2.19 [ ] Emtricitabine- Tenofovir [ ] 2.39 [ ] 1.75 [ ] Trihexyphenidyl [ ] 1.92 [ ] 2.02 [1-4.3] Salmeterol [ ] 2.14 [ ] 1.86 [ ] Cisapride [ ] 2.12 [ ] 1.84 [1-3.4] Hydrocodone- Ibuprofen [ ] 1.03 [ ] 3.26 [ ] Multivitamin With Minerals [ ] 2.31 [ ] 1.57 [ ] Valdecoxib [ ] 1.87 [ ] 2.27 [ ] Hepatitis B Immune Globulin [1-3.6] 2.8 [ ] 0.88 [ ] Valproic Acid [ ] 1.56 [1-2.5] 2.12 [1.5-3] Tuberculin Purified Protein Derivative [ ] 1.86 [ ] 1.96 [ ] Nafcillin [ ] 1.9 [ ] 1.79 [ ] Mexiletine [1-3.5] 3.36 [ ] 1.21 [ ] Tetracaine Ophthalmic [ ] 1.45 [ ] 2.41 [ ] Acetaminophen- Tramadol [ ] 2.19 [ ] 1.54 [0.8-3] Bupropion [1.7-2] 1.89 [ ] 1.89 [ ] Flunisolide [ ] 2.38 [ ] 1.28 [ ] Ticarcillin- Clavulanate [ ] 3.75 [ ] 0.87 [ ] Rofecoxib [ ] 2.02 [ ] 1.68 [ ] Coal Tar Topical [0.7-5] 2 [ ] 1.67 [ ] Citric Acid- Potassium Citrate [ ] 3.2 [ ] 0.84 [ ]
12 C. Top 100 lab-tests associated with suicidal behavior. Each test is shown with its associated result in brackets encoded as: N=negative, H=high, L=low, A=abnormal, and U=un-interpretable. Lab Test (result) Cases (1:100k) Controls (1:100k) TOTAL Women Men Risk Score [95% CI] Risk Score [95% CI] Risk Score [95% CI] Norchlordiazepoxide [Presence] in Serum or Plasma (N) [ ] [ ] 15.4 [ ] Chlordiazepoxide Plasma by Screen method (N) [ ] [ ] [ ] Demoxepam [Mass/volume] in Serum or Plasma (N) [ ] [ ] [ ] Cocaethylene [Presence] in Serum or Plasma (N) [ ] [ ] [ ] Methadone [Mass/volume] in Serum or Plasma by Screen method (N) [ ] [ ] [ ] Alprazolam [Mass/volume] in Serum or Plasma (N) [ ] [ ] [ ] Cocaine [Presence] in Serum or Plasma (N) [ ] [ ] 12.8 [ ] Nordiazepam Plasma by Screen method (N) [ ] [ ] [ ] Oxazepam [Mass/volume] in method (N) [ ] [ ] [ ] Clonazepam [Mass/volume] in Serum or Plasma by Screen method (N) [ ] [ ] [ ] Diazepam [Mass/volume] in method (N) [ ] 14.1 [ ] [ ] Norpropoxyphene Plasma by Screen method (N) [ ] [ ] [6.9-20] M-chlorophenylpiperazine [Presence] in Serum or Plasma (N) [ ] [ ] 9.89 [7-13.9] Diphenhydramine Plasma by Screen method (N) [ ] [ ] [ ] Fluoxetine [Mass/volume] in method (N) [ ] [ ] 9.47 [ ] Norfluoxetine Plasma by Screen method (N) [ ] [ ] 8.77 [ ]
13 Trazodone [Mass/volume] in method (N) [ ] [9.5-15] 8.73 [6.9-11] Paroxetine [Presence] in Serum or Plasma (N) [ ] [ ] 7.45 [ ] Ibuprofen [Mass/volume] in method (N) [ ] 12.5 [ ] 7.31 [5-10.7] Opiates [Presence] in Urine (H) [ ] 8.36 [ ] 9.12 [6.9-12] Cocaine [Presence] in Serum or Plasma by Screen method (H) [ ] [ ] 7.45 [ ] Sertraline [Presence] in Serum or Plasma (N) [ ] [8-14.8] 7.67 [ ] Norsertraline [Presence] in Serum or Plasma (N) [ ] [7.9-14] 7.17 [ ] Amitriptyline [Mass/volume] in Serum or Plasma by Screen method (N) [ ] 8.12 [4.7-14] 8.98 [ ] Acetaminophen Plasma by Screen method (L) [7-10.8] [ ] 7.25 [ ] Nortriptyline [Mass/volume] in Serum or Plasma by Screen method (N) [ ] 7.95 [5-12.5] 9.1 [6-13.8] Salicylates [Mass/volume] in method (N) [ ] 9.28 [ ] 7.37 [ ] Oxycodone [Presence] in Serum or Plasma (N) [6.3-11] 8.9 [ ] 7.31 [ ] Venlafaxine [Presence] in Serum or Plasma (N) [ ] 9.54 [6.5-14] 6.01 [ ] Benzodiazepines [Presence] in Serum or Plasma (A) [ ] 6.68 [ ] 8.06 [ ] Lorazepam [Mass/volume] in Serum or Plasma by Screen method (N) [6-9.7] 9.65 [ ] 6.01 [ ] Carbamazepine Plasma by Screen method (N) [ ] 8.85 [5.2-15] 5.98 [ ] Salicylates [Mass/volume] in Serum or Plasma (N) [ ] 7.47 [5.1-11] 6.6 [ ] Benzoylecgonine [Presence] in Urine (A) [ ] 8.51 [ ] 5.46 [ ] Ethanol [Presence] in Urine (N) [ ] 5.9 [4.4-8] 8.12 [6-11] Benzodiazepines [Presence] in Urine (A) [5.7-8] 6.85 [ ] 6.53 [ ] Acetaminophen Plasma (N) [ ] 7.44 [ ] 5.78 [4.2-8] Ethanol [Mass/volume] in Blood (N) [ ] 7.81 [ ] 5.43 [4.9-6]
14 Deprecated Tetrahydrocannabinol [Presence] in Urine by Screen method (H) [5-8.6] 6.85 [ ] 5.8 [ ] Hepatitis C virus Ab [Presence] in Serum (A) [ ] 6.37 [ ] 6.01 [ ] Benzodiazepines [Presence] in Urine (H) [ ] 5.85 [ ] 5.88 [ ] Deprecated Tetrahydrocannabinol [Presence] in Urine by Screen method (N) [ ] 6.18 [ ] 5.66 [ ] Tricyclic antidepressants [Presence] in Serum or Plasma (A) [ ] 7.25 [4.4-12] 4.9 [3-8.1] Amphetamines [Presence] in method (N) [ ] 6.2 [ ] 5.5 [ ] Lithium [Mass/volume] in Serum or Plasma (L) [ ] 6.98 [ ] 4.83 [ ] Amitriptyline [Mass/volume] in Serum or Plasma (N) [ ] 4.69 [2.7-8] 8.39 [ ] Opiates [Presence] in Urine (A) [ ] 6.42 [ ] 4.96 [ ] Lithium [Mass/volume] in Serum or Plasma (N) [ ] 7.03 [ ] 4.32 [ ] Cocaine [Presence] in Serum or Plasma by Screen method (N) [5-6.3] 5.57 [ ] 5.34 [ ] Cannabinoids [Presence] in Urine by Screen method (N) [ ] 4.85 [ ] 6 [ ] Amitriptyline+Nortriptyline Plasma (N) [ ] 5.33 [ ] 5.44 [ ] Salicylates [Presence] in Serum or Plasma (L) [ ] 5.06 [ ] 5.03 [ ] Ethanol [Mass/volume] in Blood (H) [ ] 5.16 [ ] 4.63 [ ] Methanol [Mass/volume] in Serum or Plasma (N) [4-6.4] 5.32 [ ] 4.41 [ ] Lithium [Moles/volume] in Serum or Plasma (L) [ ] 3.91 [ ] 5.78 [ ] Lamotrigine [Mass/volume] in Serum or Plasma by Screen method (N) [ ] 6.39 [ ] 3.68 [1.5-9] Isopropanol [Mass/volume] in Serum or Plasma (N) [4-6.3] 5.51 [ ] 4.31 [ ] Ethanol [Mass/volume] in Serum or Plasma (U) [ ] 6.96 [4.8-10] 3.62 [2.6-5] Cannabinoids [Units/volume] in Urine (A) [ ] 5.17 [ ] 4.42 [ ] Gabapentin [Mass/volume] in Serum or Plasma (N) [ ] 5.45 [3.3-9] 4.37 [ ] Acetaminophen [Presence] in Urine (N) [ ] 5.35 [ ] 4.29 [ ]
15 Amphetamines [Presence] in Urine (A) [ ] 7.6 [ ] 2.76 [ ] Methamphetamine [Presence] in Urine (N) [ ] 5.21 [ ] 4.26 [ ] Metoprolol [Presence] in method (N) [2.8-8] 4.83 [2.1-11] 4.43 [ ] Clozapine [Mass/volume] in Serum or Plasma (N) [ ] 6.09 [ ] 3.63 [ ] Benzodiazepines [Presence] in Urine by Screen method (N) [3.1-7] 3.86 [2-7.5] 5.12 [ ] Tricyclic antidepressants [Presence] in Urine (N) [ ] 5.01 [ ] 4.15 [ ] Phenytoin [Mass/volume] in method (N) [ ] 4.48 [ ] 4.3 [3-6.2] Barbiturates [Presence] in Urine by Screen method (N) [ ] 4.3 [ ] 4.66 [ ] Phencyclidine [Mass/volume] in Urine (N) [ ] 4.06 [ ] 4.63 [ ] Imipramine+Desipramine Plasma (N) [2.5-8] 3.72 [ ] 5.15 [ ] Tetrahydrocannabinol [Presence] in Urine (A) [ ] 4.27 [ ] 4.31 [ ] Lithium [Moles/volume] in Serum or Plasma (N) [3.2-6] 5.11 [ ] 3.64 [ ] Hepatitis C virus RNA [Units/volume] (viral load) in Serum or Plasma by Probe and target amplification method (H) [3-6.4] 6.21 [ ] 3.18 [ ] Salicylates [Mass/volume] in Serum or Plasma (L) [ ] 4.81 [ ] 3.8 [ ] Benzoylecgonine [Presence] in Urine (N) [ ] 4.48 [ ] 3.99 [ ] Barbiturates [Presence] in Urine (A) [ ] 6.72 [ ] 2.16 [1-4.9] Ethanol [Presence] in Blood (U) [ ] 4.58 [ ] 3.52 [ ] Phencyclidine [Presence] in Urine (N) [ ] 4.32 [4-4.6] 3.72 [3.5-4] Ethanol [Mass/volume] in Serum or Plasma (N) [ ] 4.37 [3.8-5] 3.72 [ ] Amphetamine [Presence] in Urine by Screen method (N) [ ] 4.23 [ ] 3.94 [ ] Oxycodone [Presence] in Urine (H) [2.3-7] 8.12 [4.1-16] 1.74 [ ] Benzodiazepines [Presence] in Serum or Plasma (N) [ ] 4.4 [4-4.9] 3.54 [ ] Hepatitis C virus RNA [Units/volume] (viral load) in Serum or Plasma by Probe and target amplification method (N) [ ] 3.85 [ ] 3.82 [ ]
16 Hepatitis C virus genotype [Identifier] in Serum or Plasma by Probe and target amplification method (N) [ ] 3.37 [ ] 3.92 [ ] Cannabinoids [Units/volume] in Urine (N) [ ] 3.81 [ ] 4.24 [ ] Valproate [Mass/volume] in Serum or Plasma (L) [ ] 4.41 [ ] 3.41 [ ] Lidocaine [Mass/volume] in method (N) [ ] 5.34 [ ] 2.96 [ ] Tetrahydrocannabinol [Presence] in Urine (N) [3.7-4] 4.01 [ ] 3.54 [ ] Cocaine [Presence] in Urine (N) [ ] 4.25 [ ] 3.44 [ ] Acetaminophen Plasma (L) [ ] 4.16 [ ] 3.44 [3-3.9] Amphetamines [Presence] in Urine (N) [3.7-4] 3.89 [ ] 3.58 [ ] Barbiturates [Presence] in Serum, Plasma or Blood (N) [ ] 4.07 [ ] 3.38 [3-3.8] Barbiturates [Presence] in Urine (N) [ ] 3.85 [ ] 3.55 [ ] Theophylline [Mass/volume] in Blood (L) [ ] 5.98 [3.3-11] 1.94 [ ] Opiates [Presence] in Urine (N) [ ] 3.78 [3.5-4] 3.39 [ ] Tricyclic antidepressants [Presence] in Serum or Plasma (N) [ ] 3.86 [ ] 3.3 [3-3.6] Salicylates [Mass/volume] in method (L) [ ] 4.18 [ ] 3.08 [ ] Benzodiazepines [Presence] in Urine (N) [ ] 3.69 [3.5-4] 3.38 [ ] Valproate [Mass/volume] in Serum or Plasma (N) [ ] 3.94 [ ] 3.13 [ ]
17 Table S-3 - Overall model performance by age and gender (based on testing-cohort). Accuracy: the percentage of correct predictions made out of all predictions; PPV: Positive Predictive Value; NPV: Negative Predictive Value. Age Accuracy Sensitivity Specificity PPV NPV MEN (AUC=0.76) WOMEN (AUC=0.77)
INTOXICATION DEATHS ASSOCIATED WITH DRUGS OF ABUSE OR ALCOHOL BALTIMORE, MARYLAND QUARTERLY REPORT: FOURTH QUARTER, 2008 AND 2008 SUMMARY
INTOXICATION DEATHS ASSOCIATED WITH DRUGS OF ABUSE OR ALCOHOL BALTIMORE, MARYLAND QUARTERLY REPORT: FOURTH QUARTER, 2008 AND 2008 SUMMARY A report from the Office of Epidemiology and Planning Baltimore
More informationINTOXICATION DEATHS ASSOCIATED WITH DRUGS OF ABUSE OR ALCOHOL BALTIMORE CITY
2009 FINAL REPORT INTOXICATION DEATHS ASSOCIATED WITH DRUGS OF ABUSE OR ALCOHOL BALTIMORE CITY This report was prepared by: Dr. Jose Arbelaez, M.D. of Baltimore Substance Abuse Systems, and Ryan J. Petteway,
More informationForensic Toxicology Scope of Testing and Detection Limits
Forensic Toxicology Scope of Testing and Detection Limits Table of Contents QUALITATIVE ANALYSES... 2 Volatile Screen by GC/FID... 2 Carbon Monoxide by Microdiffusion... 2 Ethylene Glycol by GC/MS... 2
More informationALAMEDA COUNTY BEHAVIORAL HEALTH CARE SERVICES MEDICATION FORMULARY
ANTIDEPRESSANTS Serotonin Selective Reuptake Inhibitors citalopram 10, 20, 40 mg, 10 mg/5cc $ 0.40 No escitalopram 10, 20 mg $ 2.60 Yes fluoxetine 10, 20 mg, 20 mg/5 ml $ 0.40 Yes fluvoxamine 25, 50, 100
More information3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D years
Drug Adherence Assessment Report CleanAssure TM (DRIED BLOOD SPOT): Detection Range see NOTES. Prescribed Medications: HYDROMORPHONE (DILAUDID, EXALGO), CYCLOBENZAPRINE (FLEXERIL), METHADONE (METHADOSE),
More information3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D years
Drug Adherence Assessment Report CleanAssure TM (DRIED BLOOD SPOT): Detection Range see NOTES. Prescribed Medications: NO MEDICATION LIST PROVIDED CONSISTENT RESULTS - MEDICATION DETECTED (PARENT DRUG
More information3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D Director: David J.
Drug Adherence Assessment Report Prescribed Medications: NO MEDICATION LIST PROVIDED CONSISTENT RESULTS - REPORTED MEDICATION DETECTED (PARENT DRUG AND/OR METABOLITE) REPORTED PRESCRIPTION FLAG ANTICIPATED
More informationDynacare Laboratories
Dynacare Laboratories Affiliated with Froedtert & the Medical College of Wisconsin January 2015 2015 CPT Code Updates Dear Client: The American Medical Association (AMA) publishes the Current Procedural
More informationPROGRAM General Information
Association for Quality Assessment in TDM and Clinical Toxicology Section of the Dutch Foundation for Quality Assessment in Medical Laboratories PROGRAM 2016 General Information P.O. Box 43100, 2504 AC
More informationDrug Adherence Assessment Report
Prescribed Medications: Drug Adherence Assessment Report FENTANYL, OXYCODONE CONSISTENT RESULTS - REPORTED MEDICATION DETECTED (PARENT DRUG AND/OR METABOLITE) REPORTED ANTICIPATED TEST PRESCRIPTION (S)
More informationMedications and Children Disorders
Mental Health Comprehensive Services Providing Family Stability and Developing Life Coping Skills Medications and Children Disorders Psychiatric medications can be an effective part of the treatment for
More informationGuidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Gene(s)/Level of evidence
Drug Gene(s)/Level of evidence Guidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Haloperidol CYP2D6 ( SLC6A5 ( 2D6: DPWG guidelines Reduce dose by 50% in PMs Aripiprazole
More informationManual of Clinical Psychopharmacology
Manual of Clinical Psychopharmacology Fourth Edition Alan F. Schatzberg, M.D. Kenneth T. Norris, Jr., Professor and Chairman, Department of Psychiatry and Behavioral Sciences, Stanford University School
More informationGUIDELINES FOR THE USE OF PSYCHOACTIVE MEDICATIONS IN INDIVIDUALS WITH CO-OCCURRING SUBSTANCE USE DISORDERS
City and County of San Francisco Mayor Gavin Newsom Department of Public Health Community Behavioral Health Services 1380 Howard Street 5 th Floor San Francisco, CA 94103 GUIDELINES FOR THE USE OF PSYCHOACTIVE
More informationNorthSTAR. Pharmacy Manual
NorthSTAR Pharmacy Manual Revised October, 2008 Table of I. Introduction II. III. IV. Antidepressants New Generation Antipsychotic Medications Mood Stabilizers V. ADHD Medications VI. Anxiolytics and Sedative-Hypnotics
More informationSafe transfer of prescribing guidance
Safe transfer of prescribing guidance TEWV Prescriber Summary Application required before prescribing Products requiring an application, before prescribing, using the single application form Unlicensed
More informationMedicines Formulary BNF Section 4 Central Nervous System
Medicines BNF Section 4 4.1 Hypnotics and anxiolytics Chloral Hydrate 500mg/5ml Solution Clomethiazole 192mg Capsules Lormetazepam Tablets Melatonin Capsules Nitrazepam Suspension Nitrazepam Tablets Temazepam
More information2015 Annual Physician Notice
0 Annual Physician Notice The Office of Inspector General (OIG) recommends clinical laboratories send notices to physicians and other providers who use their services, at least once a year, to inform the
More informationDrugs Found in Medical Examiner Cases
s Found in Medical Examiner Cases 1,1 difluoroethane propellant in aerosols 10-Hydroxycarbazepine 11-Hydroxy Delta-9 THC 6-monoacetylmorphine 7-amino clonazepam acetaminophen acetone alpha-hydroxyalprazolam
More informationReview of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course)
Review of Psychotrophic Medications (An approved North Carolina Division of Health Services Regulation Continuing Education Course) Common Psychiatric Disorders *Schizophrenia *Depression *Bipolar Disorder
More informationSouth London and the Maudsley NHS Foundation Trust Medicines Formulary
South London and the Maudsley NHS Foundation Trust Medicines Formulary Medicine Formulations Restrictions Additional Information / Related NICE Technology Appraisal 4.1 Hypnotics and anxiolytics 4.1.1
More informationUse of Psychotropic Medications in Older Adults with Dementia!
Use of Psychotropic Medications in Older Adults with Dementia! Deepa Pattani, PharmD, RPh Owner: PrevInteract Health Deepa.Pattani@PrevInteract.com 972-372-9775 About Me Deepa Pattani, PharmD, RPh with
More informationPSYCHIATRY DRUG ALERTS, VOLUME XXVIII, 2014 INDEX
A acamprosate ADHD Generic Methylphenidate Equivalence, 84 Methylphenidate in Pregnancy, 9 Stimulants in Pregnancy, 50 adverse effects Antidepressant-Induced Jitteriness, 94 Antidepressants and Sexual
More informationMay Revised Urine Drug Screen Test Menu Effective mid-june Lauren Anthony, MD, MT(ASCP) SBB Medical Director, Allina Health Laboratory
May 2014 Lauren Anthony, MD, MT(ASCP) SBB Medical Director, Allina Health Laboratory Revised Urine Drug Test Menu Effective mid-june 2014 To better address the complexities of drug screening for different
More informationAlcohol. Ethanol Highlands Parkway, Suite 100 Smyrna, GA 30082
Alcohol The alcohol of interest is ethanol. Ethanol has a sedative effect in the brain. Ethanol intoxication symptoms include blurred vision, slurred speech, poor coordination and difficulty thinking depending
More informationTherapeutic Drugs Monitoring TDM 2018 Therapeutic Drugs Monitoring Scheme Application Form
complete all sections below and return to LGC Standards Proficiency Testing by email, fax or post. Returning customer Lab ID: TM Purchase order no.: (compulsory) TDM Distribution Schedule Samples for the
More informationPsychotropic Medication Use in Dementia
Psychotropic Medication Use in Dementia Marie A DeWitt, MD Diplomate of the American Board of Psychiatry and Neurology, Specialization in Psychiatry & Subspecialization in Geriatric Psychiatry Staff Physician,
More informationPrescriber s Guide. Stahl s Essential Psychopharmacology
Stahl s Essential Psychopharmacology Prescriber s Guide FIFTH EDITION With the range of psychotropic drugs expanding and the usages of existing medications diversifying, we are pleased to present this
More informationMEDICARE LOCAL COVERAGE DETERMINATION COMMONLY USED DIAGNOSIS CODES
MEDICARE LOCAL COVERAGE DETERMINATION COMMONLY USED DIAGNOSIS CODES Urine drug testing (UDT) provides objective information to assist clinicians in identifying the presence or absence of drugs or drug
More informationIndex. Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) b-adrenergic blockers
Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) a-adrenergic blockers for PTSD, 798 b-adrenergic blockers for PTSD, 798 Adrenergic
More informationC O P E. Milwaukee County Opioid-Related Overdose Report MILWAUKEE COMMUNITY OPIOID PREVENTION EFFORT
Milwaukee County Opioid-Related Overdose Report 2012 2016 MILWAUKEE C O P E COMMUNITY OPIOID PREVENTION EFFORT For additional information or if you have questions about the data presented in this report,
More informationDrugSmartCup & DrugSmartDip Accuracy Report as produced by Ameditech, Inc.
Accuracy The accuracy of the DrugSmart Drugs of Abuse Tests was evaluated in comparison to commercially available drug screen tests. Sixty (60) negative urine samples collected from presumed non-user volunteers
More informationPolicy Evaluation: Low Dose Quetiapine Safety Edit
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University 500 Summer Street NE, E35, Salem, Oregon 97301 1079 Phone 503 947 5220 Fax 503
More informationEvaluation of the Impact of Expanding ELISA Screening in DUID Investigations. Aileen Lu*, Karen S. Scott, Aya Chan-Hosokawa, and Barry K.
Evaluation of the Impact of Expanding ELISA Screening in DUID Investigations Aileen Lu*, Karen S. Scott, Aya Chan-Hosokawa, and Barry K. Logan FSF Emerging Forensic Scientist Award Oral Presentation Disclosure
More informationPSYCHIATRY INTAKE FORM
Please complete all information on this form. PSYCHIATRY INTAKE FORM Name Date Date of Birth Primary Care Physician Current Therapist/Counselor What are the problem(s) for which you are seeking help? 1.
More informationPhysician s Reference for Urine and Blood Drug Testing and Interpretation
Physician s Reference for Urine and Blood Drug Testing and Interpretation DETECTIMED PANEL Urine (test code 70195) Screen Confirmation Screen Confirmation Alcohol Ethanol Amphetamines Amphetamine Methamphetamine
More informationOhana Community Care Services (CCS) Comprehensive Preferred Drug List (List of Covered Drugs)
2015 Ohana Community Care Services (CCS) Comprehensive referred Drug List (List of Covered Drugs) Ohana Health lan 00 lease read: This document contains information about the drugs we cover in this plan.
More informationHEDIS BEHAVIORAL HEALTH RESOURCE GUIDE
HEDIS BEHAVIORAL HEALTH RESOURCE GUIDE What is HEDIS? 3 HEDIS Reference Guide for Behavioral Health 4 Behavioral Health HEDIS Measures 13 WHAT IS HEDIS? HEDIS (Healthcare Effectiveness Data and Information
More informationTherapeutic Drugs Monitoring TDM 2016 Therapeutic Drugs Monitoring Scheme Application Form
complete all sections below and return to LGC Standards Proficiency Testing by email, fax or post. Returning customer Lab ID: TM Purchase order no.: (compulsory) TDM Distribution Schedule Samples for the
More information2012 DRUG RELATED DEATH STATISTICS JANUARY 1, 2012 THROUGH DECEMBER 31, 2012
JANUARY 1, 2012 THROUGH DECEMBER 31, 2012 All deaths counted in the column labeled ACCIDENTAL OVERDOSE were the direct result of the drugs ingested by the decedent. The drugs noted as being present came
More informationDrugs, Sleep & Wakefulness. Brian Koo Reena Mehra MD MS Kingman Strohl MD
Drugs, Sleep & Wakefulness Brian Koo Reena Mehra MD MS Kingman Strohl MD Things To Keep In Mind Many drugs effect sleep either causing insomnia or sedation Disruption of sleep and wakefulness may not be
More informationCross-reactivity reactivity in EMIT
Blood Drug Analysis at the State Bureau of Investigation Crime Laboratory Richard W. Waggoner, Jr. Sample Requirements 2-10 ml gray top vacutainers At least 10 ml of urine sample for drug facilitated sexual
More informationMedicine Related Falls Risk Assessment Tool (MRFRAT)
Medicine Related Falls Risk Assessment Tool (MRFRAT) The Medicine Related Falls Risk Assessment tool (MRFRAT) in Appendix 1 is designed to help identify patients at risk of falls due to their current medicine
More informationCHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XIV, 2012 INDEX
A Adderall Counterfeit, 31 addiction, internet CBT, 55 ADHD Adjunctive Guanfacine, 11 Counterfeit Adderall, 31 Developmental Trajectory and Risk Factors, 5 Dopamine Transporter Alterations, 14 Extended-Release
More informationRichard Heidenfelder M.D. Child, Adolescent and Adult Psychiatry 447 9th Ave San Diego, CA
*We are not accepting any New Patients who are currently taking any controlled pain medications *We are *Note: not completion accepting of the any following New Patients paperwork who and Initial are Screening
More informationMental Health DNA Insight WHITE PAPER
Mental Health DNA Insight WHITE PAPER JULY 2016 Mental Health DNA Insight / White Paper Mental Health DNA Insight Pathway Genomics Mental Health DNA Insight test is aimed to help psychiatrists, neurologists,
More informationStudy Guidelines for Quiz #1
Annex to Section J Page 1 Study Guidelines for Quiz #1 Theory and Principles of Psychopharmacology, Classifications and Neurotransmitters, Anxiolytics/Antianxiety/Minor Tranquilizers, Stimulants, Nursing
More information1/27/ New Release, Quest Diagnostics Nichols Institute, Valencia
NEW TESTS Please Note: Not all test codes assigned to each assay are listed in the table of contents. Please refer to the complete listing on the page numbers indicated. Test Code Test Name Effective Date
More informationSupplementary Online Content
Supplementary Online Content Blumenthal SR, Castro VM, Clements CC, et al. An electronic health records study of long-term weight gain following antidepressent use. JAMA Psychiatry. Published online June
More informationClinical Guideline for the Management of Bipolar Disorder in Adults
Clinical Guideline for the Management of Bipolar Disorder in Adults Goal: To improve the quality of life of adults with bipolar disorder Identification and Treatment of Bipolar Disorder Criteria for Diagnosis:
More informationRetrospective Drug Use Review for the Use of Psychotropic Medications in Children
Retrospective Drug Use Review for the Use of Psychotropic Medications in Children Recommendations Send providers an annual request for additional clinical data for children receiving any of the following
More informationUrine Drug Testing Methods 3-5
Urine Drug Testing Methods 3-5 Type of Test Logistics Pearls Initial Screening Test: Immunoassay Confirmatory Test: Gas chromatography-mass spectrometry (GCMS) + or Liquid chromatography-mass spectrometry
More informationThe Role of Opioid Overdoses in Confirmed Maternal Deaths,
The Role of Opioid Overdoses in Confirmed Maternal Deaths, 2012-2015 Introduction The Department of State Health Services (DSHS) conducted an analysis of maternal deaths resulting from drug overdoses from
More informationJudges Reference Table for the March 2016 Psychotropic Medication Utilization Parameters for Foster Children
Judges Reference Table for the Psychotropic Medication Utilization Parameters for Foster Children Stimulants for treatment of ADHD Preschool (Ages 3-5 years) Child (Ages 6-12 years) Adolescent (Ages 13-17
More informationSAMPLE REPORT MENTAL HEALTH DNA INSIGHT LABORATORY INFO. Protected Health Information. SSRIs. TCAs. Other Antidepressants
Test Results Reviewed & Approved by: Laboratory Director, Nilesh Dharajiya,.D. ENTAL HEALTH DNA INSIGHT PERSONAL DETAILS DOB Jan 1, 19XX ETHNICITY Caucasian ORDERING HEALTHCARE PROFESSIONAL Glenn Braunstein.D.
More informationAppendix: Psychotropic Medication Reference Tables
Appendix: Psychotropic Medication Reference Tables How to Use these Tables These reference tables are designed to provide clinic staff with specific medication related criteria for the Polypharmacy, Cardiometabolic
More informationDual Diagnosis: Substance Abuse and Mental Illness
Dual Diagnosis: Substance Abuse and Mental Illness and a review of the major PSYCHIATRIC MEDICINES Mark Stanford, Ph.D. Santa Clara Valley Health & Hospital System Department of Alcohol & Drug Services
More informationPalliative Care Drug Plan (Plan P) Formulary List of drugs PharmaCare covers
Palliative Care Drug Plan (Plan P) Formulary List of drugs PharmaCare covers This formulary is current as of February 11, 2010. Important Notes: Pharmacists must submit a claim on PharmaNet at the time
More informationPsychotropic Medications Archana Jhawar, PharmD, BCPP Clinical Faculty of UIC Pharmacy Practice Clinical Psychiatric Pharmacist Jesse Brown VA
Psychotropic Medications Archana Jhawar, PharmD, BCPP Clinical Faculty of UIC Pharmacy Practice Clinical Psychiatric Pharmacist Jesse Brown VA Goals of Medications Use least number at lowest dose to get
More informationGuide to Psychiatric Medications for Children and Adolescents
Guide to Psychiatric Medications for Children and Adolescents by Glenn S. Hirsch, M.D. The following guide includes most of the medications used to treat child and adolescent mental disorders. It lists
More informationMedicine Related Falls Risk Assessment Tool (MrFRAT) User Guide for Age Related Residential Care Facility Staff in Hawke s Bay
Medicine Related Falls Risk Assessment Tool (MrFRAT) User Guide for Age Related Residential Care Facility Staff in Hawke s Bay (Revised edition November 2015) The Medicine Related Falls Risk Assessment
More informationThe use of prescription psychotropic medication in
DRUGS AND PHARMACOLOGY Effect of Age on the Profile of Psychotropic Users: Results from the 2010 National Ambulatory Medical Care Survey Donovan T. Maust, MD,* David W. Oslin, MD, and Steven C. Marcus,
More informationIntroduction to Drug Treatment
Introduction to Drug Treatment LPT Gondar Mental Health Group www.le.ac.uk Introduction to Psychiatric Drugs Drugs and Neurotransmitters 5 Classes of Psychotropic medications Mechanism of action Clinical
More informationLearning objectives: Become aware of a new treatment for bipolar disorder.
Learning objectives: Become aware of a new treatment for bipolar disorder. Identify possible mechanisms that could explain the efficacy of this treatment. Learn about the role of nutrient deficiency in
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Neuropathic pain pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist
More informationPOSTPARTUM MOOD DISORDERS Identification and Treatment Cheryl Carroll CNM, PMHNP Psych Retreat Greensboro, NC
POSTPARTUM MOOD DISORDERS Identification and Treatment Cheryl Carroll CNM, PMHNP 2017 Psych Retreat Greensboro, NC Postpartum Depression DSM 5 Major Depressive Disorder Diagnostic Criteria specifer: with
More informationChapter 4 ~ Central nervous system
Chapter 4 ~ Central Nervous System: Special Section 1 of 5 Chapter 4 ~ Central nervous system 4.1 Hypnotics and anxiolytics 4.1.1 Hypnotics LOPRAZOLAM Tablet 1mg LORMETAZEPAM Tablet 500microgram PROMETHAZINE
More informationPregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition)
Pregnancy General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition) In all women of child bearing potential Always discuss the possibility of pregnancy; half of all pregnancies are unplanned
More informationMental Health Intake Form
Current Symptoms Checklist: (check once for any symptoms present, twice for major symptoms) ( ) ( ) Depressed mood ( ) ( ) Racing thoughts ( ) ( ) Excessive worry ( ) ( ) Unable to enjoy activities ( )
More informationSupplementary Online Content
Supplementary Online Content Huybrechts KF, Hernández-Díaz S, Patorno E, et al. Antipsychotic use in pregnancy and the risk for congenital malformations. JAMA Psychiatry. Published online August 17, 2016.
More informationNew Patient Questionnaire
4 Embarcadero Center, Suite 1400, San Francisco, CA 94111 (415) 926-7774 phone; (415) 591-7760 office@sanfranciscopsych.com New Patient Questionnaire Thank you for trusting San Francisco Psychiatry with
More informationREVIEW ARTICLE MANAGEMENT OF PATIENTS WITH MOOD DISORDERS AND COMORBID SUDS
MANAGEMENT OF PATIENTS WITH MOOD DISORDERS AND COMORBID SUDS ANNALS OF CLINICAL PSYCHIATRY 2012;24(1):38-55 REVIEW ARTICLE The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations
More informationIMPORTANT NOTICE. Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members
IMPORTANT NOTICE Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members These changes apply only to members covered under the DC Healthcare Alliance program Alliance
More informationDisclosure. Objectives: Technician. Objectives: Pharmacist. Diagnostic and Statistical Manual (DSM-V) The Face of Mental Illness 7/25/2015
49th Annual Meeting Psychiatry for the Non-Psychiatry Specialist Jacintha Cauffield, PharmD, BCPS, CDE Associate Professor of Pharmacy Practice Lloyd L. Gregory School of Pharmacy Palm Beach Atlantic University
More informationOverview and Update on Current Psychopharmacological Medications, Including New Medications in Clinical Trials
SPEAKER NOTES Overview and Update on Current Psychopharmacological Medications, Including New Medications in Clinical Trials Summarized by Thomas T. Thomas New psychotropic medications are coming on the
More informationEffective Date: Approved by: Laboratory Executive Director, Ed Hughes (electronic signature)
1 Policy #: 803 (PLH-803-02) Effective Date: NA Reviewed Date: 4/11/2008 Subject: URINE DRUG SCREENS Approved by: Laboratory Executive Director, Ed Hughes (electronic signature) Approved by: Laboratory
More informationHappy Daisy Ltd. New Client intake Form. What are the issues for which you are seeking care?
Happy Daisy Ltd. New Client intake Form Name Date Preferred name Pronouns Referred by Date of birth Age Race What are the issues for which you are seeking care? 1. 2. 3. Please check of any of the symptoms
More informationSupplement: Tables and Figures
Supplement: Tables and Figures Supplement Table 1. Baseline Characteristics by Study and Efavirenz Assignment Supplement Table 2. Baseline Psychoactive Medications by Efavirenz Assignment* Supplement Table
More informationMedications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation
Medications for Anxiety & Behavior in Williams Syndrome Christopher J. McDougle, M.D. Director, Lurie Center for Autism Professor of Psychiatry and Pediatrics Massachusetts General Hospital and MassGeneral
More informationVariation in the Risk of Suicide Attempts and Completed Suicides by Antidepressant Agent in Adults
WEB-ONLY CONTENT Variation in the Risk of Suicide Attempts and Completed Suicides by Antidepressant Agent in Adults A Propensity Score Adjusted Analysis of 9 Years Data Sebastian Schneeweiss, MD, ScD;
More informationCanterbury District Health Board Endocrine Test Centre Protocols. Date Signature Next review Sign when read
0855 Prolactin Series test ASY-855.1: Associated documents Prolactin Series Test Patient information sheet Prolactin series sample request form 0 ASY-855.2: Distribution of Documents Copy No Number Location
More informationUrine Opioid Dependency Panel (UODP) 1
Drug Testing Panels Urine Opioid Dependency Panel (UODP) 1 Amphetamines Amphetamine Methamphetamine Methylenedioxyamphetamine Adderall, Dexedrine, Vyvanse, Lisdexamfetamine (Speed, Bennies, Crystal Meth,
More informationBree Collaborative AMDG Opioid Prescribing Guidelines Workgroup. Opioid Prescribing Metrics - DRAFT
Bree Collaborative AMDG Opioid Prescribing Guidelines Workgroup Opioid Prescribing Metrics - DRAFT Definitions: Days Supply: The total of all opioid prescriptions dispensed during the calendar quarter
More informationMixing and Matching: Layering Medications as Family Physicians
Mixing and Matching: Layering Medications as Family Physicians Family Medicine Forum Vancouver, B.C. November 9-12, 2016. Jon Davine, CCFP, FRCP(C) McMaster University Objectives Discuss different examples
More informationAAA. add dan campbell artwork cats? Report #12 Changes in Medication Use over Time in Adolescents and Adults with Autism Spectrum Disorders
AAA Adolescents & Adults with Autism A Study of Family Caregiving add dan campbell artwork cats? Report #12 Changes in Medication Use over Time in Adolescents and Adults with Autism Spectrum Disorders
More informationToxicological Investigation of Drug Impaired Driving Toxicology Laboratory Survey
Toxicological Investigation of Drug Impaired Driving Toxicology Laboratory Survey Kayla J. Lowrie, MS, Jennifer Turri, BS, Jill Yeakel, MSFS, Barry K. Logan, PhD, DABFT, Arcadia University, 450 S. Easton
More informationMental Health Intake Form
38600 Van Dyke Ave., Suite 200 Sterling Heights, MI 48313 Phone: (586) 933-5395 Fax: (586) 935-0159 Mental Health Intake Form Please complete all information on this form and bring it to the first visit.
More informationChapter 4 ~ Central nervous system
Chapter 4 ~ Central Nervous System: General Section 1 of 6 Chapter 4 ~ Central nervous system 4.1 Hypnotics and anxiolytics 4.1.1 Hypnotics CHLORAL HYDRATE CLOMETHIAZOLE NITRAZEPAM TEMAZEPAM TRICLOFOS
More informationPain Management and Compliance Toxicology. Greg Jellick, MSFS, D-ABFT-FT Technical Director Quality Toxicology San Antonio, TX
Pain Management and Compliance Toxicology Greg Jellick, MSFS, D-ABFT-FT Technical Director Quality Toxicology San Antonio, TX Prescription Drug Abuse: A National Problem Prescription drug abuse is a growing
More informationNSFT Formulary. Double Red Not recommended for routine use/not commissioned. These drugs have not been recommended for routine use at present.
Traffic Light Status NSFT Formulary Not recommended for routine use/not commissioned. These drugs have not been recommended for routine use at present. Hospital/Specialist only Drugs for which the Trust
More informationDrug Profiles of Apprehended Drivers in Victoria
Drug Profiles of Apprehended Drivers in Victoria J Gerostamoulos, P McCaffrey, O H. Drummer and M Odell*. Victorian Institute of Forensic Medicine, Department of Forensic Medicine, Monash University, 57-83
More informationETHNICITY AND PSYCHOTROPIC RESPONSE
Ethnic Differences in Drug Metabolism ETHNICITY AND PSYCHOTROPIC RESPONSE Bridging Cultures: Improving Evaluation & Treatment of Cognitive 8 March 28 Keh-Ming Lin, M.D., M.P.H. Professor Emeritus of Psychiatry,
More informationDealing with a Mental Health Crisis
Dealing with a Mental Health Crisis Information and Resources for First Responders P... PROFESSIONAL WHAT NAMI DOES NAMI Minnesota is a statewide 501(c)(3) grassroots nonprofit organization dedicated to
More informationFully Automated Online Sample Preparation and LC-MS/MS Analysis of Drugs of Abuse in Oral Fluids
PO-CON1753E Fully Automated Online Sample Preparation and LC-MS/MS Analysis of Drugs of Abuse in Oral Fluids ASMS 2017 TP-442 Joshua F. Emory 1, Nathan DeFreitas 2, Michael Roberts 1, Manoj Tyagi 2, M.
More informationSeptember HCMC Toxicology Transition: Additional information and Frequently Asked Questions
September 2016 HCMC Toxicology Transition: Additional information and Frequently Asked Questions Many clinicians have asked for more information about the Urine Drug Compliance Analysis (LAB8742) switch
More informationTOP APS DRUGS - DIVALPROEX SODIUM BRAND NAME: DEPAKOTE (ER)
divalproex sodium TOP APS DRUGS - DIVALPROEX SODIUM BRAND NAME: DEPAKOTE (ER) Pharmacodynamics study of what a drug does to the body Divalproex sodium is chemically compounded from sodium valproate and
More informationProfile of PAES Recipients and Factors That Influence PAES Outcomes
` San Francisco Department of Human Services County Adult Assistance Programs Personal Assisted Employment Services Program Profile of PAES Recipients and Factors That Influence PAES Outcomes Analysis
More informationEligible Beneficiaries
Therapeutic Class: Behavioral Health Medications for Adults Clinical Edit Number Long Description 4110 (May change) Quantity limit edit that is applied to atypical antipsychotics for claims identified
More information#55 PRESCRIBING AND MONITORING PSYCHI RIC MEDICATIONS
- '_ ADMINISTRA TIVE/FISCAUCLINICAL/PHF POLICY AND PROCEDURES COUNTY OF SANTA BARBARA ALCOHOL, DRUG AND MENTAL HEAL TH SERVICES Section - QUALITY ASSURANCE Effective: 12/1/09 Policy- Director's Approval
More information